Drs. Koch and Most's Heart Gene Therapy Research Featured in Philadelphia Inquirer
In recent months, researchers have reported success using gene therapy to treat common, intractable cardiac problems including heart failure, hardened arteries and atrial fibrillation.
Drs. Walter Koch and Patrick Most of the Center for Translational Medicine at Jefferson have developed a gene therapy that boosts a calcium-binding protein called S100A1. In a Philadelphia Inquirer story, Dr. Most explains, "The S100A1 gene seems to be like the coach of a football team rather than just a player."
After seeing a dramatic response in pigs with failing hearts, the Jefferson researchers are now talking to the U.S. Food and Drug Administration about trying S100A1 in humans.
Read the full "Cardiac gene therapy shows promise to save lives" article.
Publication: Philadelphia Inquirer
Published: 9/12/2011